Acacia's Euronext Listing To Help Target Unmet US PONV Market

Acacia Pharma’s long-term aim, once its go-it-alone US strategy is in hand, is to turn its attention to ex-US partnering possibilities for its lead product for post-operative nausea and vomiting. It will also develop a Phase II candidate for chemotherapy-induced nausea and vomiting.

Grand Place
The Grand Place in Brussels • Source: Shutterstock

Just over a month after the FDA accepted Acacia Pharma Ltd.'s US NDA for its novel post-operative nausea and vomiting (PONV) therapy, Baremsis (a low-dose amisulpride injection), and received a PDUFA date of Oct. 5, 2018, the Cambridge, UK-based company announced on Feb. 5 its intention to launch an initial global offering (IGO) on Euronext in Brussels, to raise new funds to support its US marketing preparations.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business